Dostarlimab (1) – Jemperli®
Endometrial carcinoma (EC), after platinum-based therapy
Characteristics
| Start date | 15.06.2021 – Marketing authorisation: 21.04.2021 |
|---|---|
| Resolution | 02.12.2021 |
| INN | Dostarlimab |
| Brand name | Jemperli® |
| Pharm. company | GlaxoSmithKline GmbH & Co. KG |
| G-BA Procedure ID | D-699 |
| ATC code | L01FF07 PD-1/PDL-1 inhibitors (L01FF) |
| DDD | 24 mg P |
| Therapeutic area | Oncological diseases |
| Reason for procedure | Initial assessment |
| Regulatory status | Conditional Approval |
| Specialty | ACT change |
Studies and Results
- Clinical trials
- The GARNET trial is an ongoing, single-arm Phase I trial.
- The ZoptEC trial is a completed randomised, controlled, open-label Phase III trial in which doxorubicin was compared with zoptarelin.
Adult female patients with recurrent or advanced endometrial carcinoma with dMMR/MSI-H in whom disease progression occurs during or after a platinum-based regimen
- An additional benefit is not proven.
- Overall, the data presented are not sufficient to demonstrate additional benefit compared with the appropriate comparator therapy; therefore, the additional benefit of dostarlimab as monotherapy in adult female patients with recurrent or advanced endometrial carcinoma with dMMR/MSI-H, in whom disease progression occurs during or after a platinum-based regimen, is not proven.
- mortality
- Patient-relevant secondary endpoints are assessed in the categories of overall survival, morbidity and health-related quality of life.
- The results from the GARNET study alone are not suitable for assessing the additional benefit of dostarlimab, as they do not allow for a comparison with the appropriate comparator therapy.
- morbidity
- Patient-relevant secondary endpoints are assessed in the categories of overall survival, morbidity and health-related quality of life.
- The primary endpoints of the study are those in the ‘side effects’ category, as well as the endpoints ‘objective response rate’ and ‘duration of response’.
- Health-related quality of life
- Patient-relevant secondary endpoints are assessed in the categories of overall survival, morbidity and health-related quality of life.
- Side effects
- The primary endpoints of the study are those in the ‘side effects’ category, as well as the objective response rate and duration of response.
- Conclusion
- Overall, the data presented are not sufficient to demonstrate additional benefit compared with the appropriate comparator therapy; therefore, the additional benefit of dostarlimab as monotherapy in adult female patients with recurrent or advanced endometrial carcinoma with dMMR/ MSI-H, in whom disease progression occurs during or after a platinum-based regimen, is not proven.
- Dostarlimab may represent a relevant treatment option in individual cases within this therapeutic indication.
Courtesy translation only, please refer to the German original.
Associated procedures
| Dostarlimab (3) | Jemperli® | GlaxoSmithKline GmbH & Co. KG | Primarily advanced or recurrent endometrial cancer with pMMR, combination with carboplatin and paclitaxel | 990–1,810 | 100% additional benefit not proven | |
| Dostarlimab (2) | Jemperli® | GlaxoSmithKline GmbH & Co. KG | Primary advanced or recurrent endometrial carcinoma with dMMR/ MSI-H, combination with carboplatin and paclitaxel | 790–1,520 | 50% Indication of major additional benefit | |
| Dostarlimab (1) | Jemperli® | GlaxoSmithKline GmbH & Co. KG | Endometrial carcinoma (EC), after platinum-based therapy | 230–3,360 | 100% additional benefit not proven |
<< List of all resolutions